Generic pharmaceutical company Armas Pharmaceuticals Inc on Monday announced the availability of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI to increase its product portfolio count to 11.

The company stated that Caffeine Citrate Injection, which the generic equivalent of Hikma's, CAFCIT, is available in 60mg/3ml, with an approximate market size of USD4m, annually.

Docetaxel Injection, which is the generic equivalent of Sanofi's, Taxotere), is available in 20mg/1ml, 80mg/4ml and 160mg/8ml, with an approximate market size of USD45m, annually.

Also, the Gemcitabine Injection, which is the generic equivalent of Eli Lilly's, Gemzar), is available in 200mg/5.26ml, 1G/26.3ml and 2G/52.6ml, with an approximate market size of USD25m, annually.

According to the company, the Verapamil HCI Injection, which is the generic equivalent of Pfizer's, Calan), is available in 5mg/2ml and 10mg/4ml, with an approximate market size of USD31m, annually.